


#3



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UROC:014USD1/TJS

Serial No.

09/660,568

Applicants

David Ralph, Gang An, S. Mark O'Hara
and Robert Veltri

Filing Date:

September 11, 2000

Group:

1635

RECEIVED

APR 25 2001

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
M	A1	5,236,844	08-17-93	Basset <i>et al.</i>	435	320.1	11-21-91
	A2	5,262,311	11-16-93	Pardee <i>et al.</i>	435	91.2	03-11-92
	A3	5,440,021	08-08-95	Chuntharapai <i>et al.</i>	530	388.22	02-25-94
	A4	5,459,037	10-17-95	Sutcliff <i>et al.</i>	435	6	11-12-93
	A5	5,539,096	07-23-96	Babaï <i>et al.</i>	536	24.3	09-08-94
	A6	5,677,125	10-14-97	Holt <i>et al.</i>	435	6	01-14-94
A	A7	5,543,296	8/6/96	Sobol <i>et al.</i>	435	6	12/16/94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
M	B1	WO 94/10343	5/11/94	Europe			
A	B2	WO 97/19097	5/29/97	Europe			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
H	C1	Alcaraz, Antonio, <i>et al.</i> , "Aneuploidy and Aneusomy of Chromosome 7 Detected by Fluorescence <i>in Situ</i> Hybridization Are Markers of Poor Prognosis in Prostate Cancer", <i>Cancer Research</i> , 54:3998-4002, 1994.
M	C2	American Type Culture Collection, "Catalogue of cell lines & hybridomas," 7th Ed. pp. 150 and 308, 1992.
A	C3	An, G., <i>et al.</i> , "Isolation of Genes differentially expressed in prostate cancer cells with metastatic potential by arbitrarily-primed differential analyses (ADA), <i>Proc. Amer. Assn. Canc. Res.</i> , 36:82, Abstract #491, 1995.

25020103.1

Examiner:

Date Considered:

5/28/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

A: 163327(25020103_1)

Form PTO-1449 (modified)

Atty. Docket No.

UROC:014USD1/TJS

Serial No.

09/660,568

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Ralph, Gang An, S. Mark O'Hara
and Robert Veltri

Filing Date:

September 11, 2000

Group:

1635

RECEIVED

APR 25 2001

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
25	C4	Andrawis <i>et al.</i> , "Expression of interleukin-8 in prostate cancer, benign prostatic hyperplasia, and bladder cancer," <i>Proc. Am. Urol. Assn.</i> , 155(5):512A, Abstract #804, 1996.
	C5	Bookstein, Robert, <i>et al.</i> , "Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated <i>RB</i> Gene", <i>Science</i> , 247:712-715, 1990.
	C6	Bookstein, Robert, <i>et al.</i> , "Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma", <i>Proc. Natl. Acad. Sci. USA</i> , 87:7762-7766, 1990.
	C7	Bova, G. Steven, <i>et al.</i> , "Homozygous Deletion and Frequent Allelic Loss of Chromosome 8p22 Loci in Human Prostate Cancer", <i>Cancer Research</i> , 53:3869-3873, 1993.
	C8	Carter, Bob S., <i>et al.</i> , "Allelic loss of chromosomes 16q and 10q in human prostate cancer", <i>Proc. Natl. Acad. Sci. USA</i> , 87:8751-8755, 1990.
	C9	Damaj <i>et al.</i> , "Identification of G-protein binding sites of the human interleukin-8 receptors by functional mapping of the intracellular loops," <i>FASEB J.</i> , 10:1426-1434, 1996.
	C10	Greene <i>et al.</i> , "Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an <i>in situ</i> messenger RNA hybridization technique," <i>Am. J. Pathol.</i> , 150(5):1571-1582, 1997.
	C11	International Search Report dated March 20, 1998 (PCT/US97/22105) (UROC:014P).
	C12	Ivanova and Belyavsky, "Identification of differentially expressed genes by restriction endonuclease-based gene expression fingerprinting," <i>Nucl. Acids Res.</i> , 23(15):2954-2958, 1995.
	C13	Macoska, Jill A., <i>et al.</i> , "Fluorescence in Situ Hybridization Analysis of 8p Allelic Loss and Chromosome 8 Instability in Human Prostate Cancer", <i>Cancer Research</i> , 54:3824-3830, 1994.
	C14	Matsushima <i>et al.</i> , "Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor," <i>J. Exp. Med.</i> , 167(6):1883-1893, 1988.
	C15	Nomura, "HumamRNA for KIAA0262 gene, complete cds," 1997, Database GenBank on STN, GenBank Accession No. D87451.
	C16	Schmid and Weissmann, "Induction of mRNA for a serine protease and a β -thromboglobulin-like protein in mitogen-stimulated human leukocytes," <i>J. Immunol.</i> , 139:250-256, 1987.

25020103.1

Examiner:

Date Considered: 5/28/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

Atty. Docket No.

UROC:014USD1/TJS

Serial No.

09/660,568

List of Patents and Publications for Applicant's

Applicants

David Ralph, Gang An, S. Mark O'Hara
and Robert Veltri

Filing Date:

September 11, 2000

Group:

1635

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
M	C17	Takahashi, Satoru, et al., "Potential Markers of Prostate Cancer Aggressiveness Detected by Fluorescence <i>in Situ</i> Hybridization in Needle Biopsies", <i>Cancer Research</i> , 54:3574-3579, 1994.
	C18	Babian <i>et al.</i> , "Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer," <i>J. Urol.</i> , 156:432-437, 1996.
	C19	Barinaga, "An intriguing new lead on Huntington's disease," <i>Science</i> , 271:1233-1234, 1996.
	C20	Brawn <i>et al.</i> , "Prostatic acid phosphatase levels (enzymatic method) from completely sectioned, clinically benign, whole prostates," <i>The Prostate</i> , 28:295-299, 1996.
	C21	Carter <i>et al.</i> , "Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase," <i>Proc. Natl. Acad. Sci. USA</i> , 93:749-753, 1996.
	C22	Carter <i>et al.</i> , "Prospective evaluation of men with stage T1C adenocarcinoma of the prostate," <i>J. Urol.</i> , 157:2206-2209, 1997.
	C23	Christensson <i>et al.</i> , "Serum prostate specific antigen complexed to α 1-antichymotrypsin as an indicator of prostate cancer," <i>J. Urol.</i> , 150:100-105, 1993.
	C24	Cooner <i>et al.</i> , "Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen," <i>J. Urol.</i> , 143:1146-1154, 1990.
	C25	di Celle <i>et al.</i> , "Cytokine gene expression in β -cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein," <i>Blood</i> , 84:220-228, 1994.
	C26	Dong <i>et al.</i> , "KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2," <i>Science</i> , 268:884-886, 1995.
	C27	Harris <i>et al.</i> , "Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less," <i>J. Urol.</i> , 157:1740-1743, 1997.
M	C28	Huang <i>et al.</i> , "Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma," <i>Prostate</i> , 23:201-212, 1993.

25020103.1

Examiner:


Date Considered:

5/29/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

A: 163327(25020103_1)



Form PTO-1449 (modified)

Atty. Docket No.

UROC:014USD1/TJS

Serial No.

09/660,568

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Ralph, Gang An, S. Mark O'Hara
and Robert Veltri

Filing Date:

September 11, 2000

Group:

1635

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
M	C29	Israeli <i>et al.</i> , "Expression of the prostate-specific membrane antigen," <i>Cancer Res.</i> , 54:1807-1811, 1994.
	C30	Jacobson <i>et al.</i> , "Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing," <i>JAMA</i> , 274:1445-1449, 1995.
	C31	Larsen <i>et al.</i> , "The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes," <i>Science</i> , 243:1464-1466, 1989.
	C32	Liang and Pardee, "Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction," <i>Science</i> , 257:967-971, 1992.
	C33	Liang <i>et al.</i> , "Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells," <i>Cancer Res.</i> , 52:6966-6968, 1992.
	C34	Lifton, "Molecular genetics of human blood pressure variation," <i>Science</i> , 272:676-680, 1996.
	C35	Lilja <i>et al.</i> , "Prostate-specific antigen in serum occurs predominantly in complex with α_1 -antichymotrypsin," <i>Clin. Chem.</i> , 37:1618-1625, 1991.
	C36	López-Nieto and Nigam, "Selective amplification of protein-coding regions of large sets of genes using statistically designed primer sets," <i>Nature Biotechnol.</i> , 14:857-861, 1996.
	C37	Marley <i>et al.</i> , "Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia," <i>Urology</i> , 48(6A):16-22, 1996.
	C38	McClelland <i>et al.</i> , Interactions among regulators of RNA abundance characterized using RNA fingerprinting by arbitrarily primed PCR™, " <i>Nucl. Acids Res.</i> , 22:4419-4431, 1994.
	C39	McCormack <i>et al.</i> , "Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era," <i>Urology</i> , 45:729-744, 1995.
	C40	Miki <i>et al.</i> , "A strong candidate for the breast and ovarian cancer susceptibility gene <i>BRCA1</i> ," <i>Science</i> , 266:66-71, 1994.
M	C41	Morahan <i>et al.</i> , "Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus," <i>Science</i> , 272:1811-1813, 1996.

25020103.1

Examiner:

Date Considered:

5/29/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

Atty. Docket No.

UROC:014USD1/TJS

Serial No.

09/660,568

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Ralph, Gang An, S. Mark O'Hara
and Robert Veltri

Filing Date:

September 11, 2000

Group:

1635

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
DA	C42	Murphy <i>et al.</i> , "Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement," <i>Prostate</i> , 26:164-168, 1995.
	C43	Murphy <i>et al.</i> , "Evaluation and comparison of two new prostate carcinoma markers," <i>Cancer</i> , 78:809-818, 1996.
	C44	Oesterling <i>et al.</i> , "Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios," <i>J. Urol.</i> , 154:1090-1095, 1995.
	C45	Oesterling, "Molecular PSA: the next frontier in Pca screening," <i>Contemporary Urol.</i> , 8:76-92, 1996.
	C46	Partin and Oesterling, "The clinical usefulness of prostate specific antigen: update 1994," <i>J. Urol.</i> , 152:1358-1368, 1994.
	C47	Partin and Oesterling, "The clinical usefulness of percent free-PSA," <i>Urology</i> , 48(6A):1-3, 1996.
	C48	Partin and Oesterling (Eds.), "The clinical usefulness of percent free prostate-specific antigen," <i>Urology</i> , 48(6A)suppl:1-87, 1996.
	C49	Pettersson <i>et al.</i> , "Free and complexed prostate-specific antigen (PSA): <i>in vitro</i> stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA- α_1 -antichymotrypsin complex," <i>Clin. Chem.</i> , 41(10):1480-1488, 1995.
	C50	Piironen <i>et al.</i> , "Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum," <i>Clin. Chem.</i> , 42:1034-1041, 1996.
	C51	Ralph and Veltri, "Prostate cancer progress," <i>Advance/Laboratory</i> , 6:51-56, 1997.
	C52	Ralph <i>et al.</i> , "RNA fingerprinting using arbitrarily primed PCR TM identifies differentially regulated RNAs in mink lung (My1Lu) cells growth arrested by transforming growth factor β 1," <i>Proc. Natl. Acad. Sci. USA</i> , 90:10710-10714, 1993.
DA	C53	Sidransky <i>et al.</i> , "Identification of p53 gene mutations in bladder cancers and urine samples," <i>Science</i> , 252:706-709, 1991.

25020103.1

Examiner:

Date Considered:

5/28/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)



Form PTO-1449 (modified)

Atty. Docket No.

UROC:014USD1/TJS

Serial No.

09/660,568

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

David Ralph, Gang An, S. Mark O'Hara
and Robert Veltri

Filing Date:

September 11, 2000

Group:

1635

U.S. Patent Documents

See Page 1



Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C54	Silver <i>et al.</i> , "Prostate-specific membrane antigen expression in normal and malignant human tissues," <i>Clin. Cancer Res.</i> , 3:81-85, 1997.
	C55	Slamon <i>et al.</i> , "Studies of the HER-2/ <i>neu</i> proto-oncogene in human breast and ovarian cancer," <i>Science</i> , 244:707-712, 1989.
	C56	Soh <i>et al.</i> , "Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?" <i>J. Urol.</i> , 157:2212-2218, 1997.
	C57	Stenman <i>et al.</i> , "A complex between prostate-specific antigen and α 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer," <i>Cancer Res.</i> , 51:222-226, 1991.
	C58	Taparowsky <i>et al.</i> , "Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change," <i>Nature</i> , 300:762-764, 1982.
	C59	Vieira <i>et al.</i> , "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI," <i>Proc. Natl. Acad. Sci. USA</i> , 88(4):1172-1176, 1991.
	C60	Welsh and McClelland, "Fingerprinting genomes using PCR TM with arbitrary primers," <i>Nucl. Acids Res.</i> , 18:7213-7218, 1990.
	C61	Welsh <i>et al.</i> , "Arbitrarily primed PCR TM fingerprinting of RNA," <i>Nucl. Acids Res.</i> , 20:4965-4970, 1992.
	C62	Zlotta <i>et al.</i> , "Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction," <i>J. Urol.</i> , 157:1315-1321, 1997.
	C63	An <i>et al.</i> , "Differential expression of full-length and a truncated Her-2/ <i>neu</i> oncogene receptor in prostate cancer assessed using relative quantitative RT-PCR," <i>Molecular Urology</i> , 2(4):305-310, 1998.
	C64	Veltri <i>et al.</i> , "Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer," <i>Urology</i> , 53(1):139-147, 1999.
	C65	Veltri <i>et al.</i> , "The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis," <i>Seminars in Urologic Oncology</i> , 16(3):106-117, 1998.

25020103.1

Examiner:

Date Considered:

5/29/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)



Form PTO-1449 (modified)

Atty. Docket No.

UROC:014USD1/TJS

Serial No.

09/660,568

List of Patents and Publications for Applicant's

Applicants

David Ralph, Gang An, S. Mark O'Hara
and Robert Veltri

Filing Date:

September 11, 2000

Group:

1635

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1




Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C66	PCT International Search Report, PCT/US99/06488, Aug. 3, 1999.
	C67	Adams <i>et al.</i> , "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence," <i>Nature</i> , 377(6547 Suppl.):3-174, GenBank Acc. No. AA310306, 1995.
	C68	Mukaida <i>et al.</i> , "Genomic Structure of the human monocyte-derived neutrophil chemotactic factor IL-8," <i>Jour. Immun.</i> , 143(4):1366-1371, Aug. 15, 1989.
	C69	Nomura <i>et al.</i> , "Prediction of the coding sequences of unidentified human genes: VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain," <i>DNA Res.</i> , 3(5):321-329, GenBank Acc. No. D87451, 1996.
	C70	Hotta <i>et al.</i> , "Coding region structure of interleukin-8 gene of human lung giant cell carcinoma LU65C cells that produce LUCT/interleukin-8:homogeneity in interleukin-8 genes," <i>Immunology Letters</i> , 24:165-170, 1990.
	C71	Sticherling <i>et al.</i> , "Production and characterization of monoclonal antibodies against the novel neutrophil activating peptide NAP/IL8," <i>Jour. Immun.</i> , 143(5):1628-1634, Sep 1, 1989.

25020103.1

Examiner: 

Date Considered: 5/28/03

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)